Pleural effusion related to IgG4

Yoriyuki Murata\textsuperscript{a,b}, Keisuke Aoe\textsuperscript{a,b}, and Yusuke Mimura\textsuperscript{a}

Purpose of review
The causes of exudative pleural effusions are diverse and frequently remain unclear despite exhaustive examinations. Recently recognized IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder that can affect nearly any organ including the lungs. This review will focus on the involvement of IgG4 in exudative pleural effusion of unknown cause.

Recent findings
IgG4 is found to be involved in a proportion of patients with undiagnosed pleural effusions. Pleural involvement in IgG4-RD can be seen in isolation or association with other organ disease. Pleural thickening and/or effusion are common clinical features of IgG4-related pleural lesions, and this condition is histologically characterized by a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells in the pleura. Although the pathogenesis of IgG4-RD is poorly understood, there is a growing body of evidence that indicates an antigen-driven process requiring T-cell and B-cell interaction in which autoantibodies, plasmablasts, follicular helper T cells and CD4\textsuperscript{+} cytotoxic T lymphocytes participate.

Summary
The possibility of IgG4-related pleural lesion should be considered in patients with pleural effusion of unexplained cause when lymphoplasmacytic infiltration is seen in a pleural biopsy specimen. This condition is responsive to systemic steroid therapy.

Keywords
corticosteroid, fibrinous pleuritis, IgG4-related disease, nonspecific pleuritis, pleural thickening

INTRODUCTION
Pleural effusion is a common presentation, originating from a wide range of disorders, including congestive cardiac failure, pneumonia and cancer [1–4]. The cause of a pleural effusion frequently remains unclear after thoracentesis. Light’s criteria are used to help differentiate exudates from transudates by measuring the protein and lactate dehydrogenase (LDH) concentrations in the pleural fluid and the serum [2,4], and algorithms for the investigation of exudative pleural effusion have been developed [1,5–7]. Nonetheless, the cause of exudative effusion remains uncertain in a substantial percentage of patients with lymphocytic pleural effusion after extensive examinations including thoracoscopic pleural biopsy [8,9]. Approximately 30\% of cases of exudative pleural effusion are reported to be diagnosed with nonspecific pleuritis, that is no specific diagnosis, even after a complete investigation including thoracoscopy, and 12–15\% of nonspecific pleuritis are ultimately diagnosed with pleural malignancy after a mean interval between thoracoscopy and the final diagnosis of 4.4–9.8 months [10,11]. Therefore, 12–16 months of follow-up is suggested following thoracscopy for patients with nonspecific pleuritis to exclude malignancy [12–16]; however, unexplained pleural effusions often present a management dilemma for clinicians because of ongoing uncertainty about the possibility of a false-negative result from sampling error. In addition, the clinical course of such pleural effusions varies, for example resolving, persistent and progressive. Hence, new approaches are needed to detect their causes. Recently, increasing attention has been drawn to IgG4-related disease (IgG4-RD), a fibroinflammatory disorder of

\textsuperscript{a}The Department of Clinical Research and \textsuperscript{b}The Department of Respiratory Medicine, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan

Correspondence to Yusuke Mimura, MD, PhD, Department of Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, 685 Higashikiwa, Ube 755-0241, Japan. Tel: +81 836 582300; fax: +81 836 585219; e-mail: mimura.yusuke.qy@mail.hosp.go.jp

Curr Opin Pulm Med 2019, 25:384–390
DOI:10.1097/MCP.0000000000000581

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
uncertain cause that affects various organs including the pleura. Several lines of evidence indicate that IgG4-RD accounts for a proportion of patients with pleural effusions of idiopathic cause.

**IgG4-RELATED DISEASE**

IgG4-RD is a chronic, systemic fibroinflammatory disorder characterized by lymphoplasmacytic infiltration of IgG4-positive plasma cells, storiform fibrosis, obliteratorive phlebitis and often but not always elevated serum IgG4 levels [17,18]. IgG4-RD was first described in the pancreas, formerly known as autoimmune pancreatitis [19], and subsequently salivary and lacrimal glands which has long been known as Mikulicz’s disease [20]. Currently, IgG4-RD is shown to affect essentially any organ system including biliary tree, kidneys, retroperitoneum, prostate, aorta, pericardium, lungs, thyroids, lymph nodes, meninges and skin.

Thoracic involvement can be seen in approximately 40% of IgG4-RD patients. In a Chinese IgG4-RD patient cohort the frequency of the thoracic involvement was reported to be 87 of 248 (35.1%) patients and pleural effusion and thickening were noted in 4.6 and 16.1%, respectively [21]. Consistent with these results, 22 of 53 (41.5%) IgG4-RD patients had pulmonary manifestations, and three of 22 (13.6%) presented with pleural thickening/effusion in a UK-based cohort of IgG4-RD patients [22]. The pleural manifestations of IgG4-RD include pleural mass, pleuritis with fibrosis (nodular or diffuse pleural thickening), and pleural effusion [23]. Although thoracic involvement in IgG4-RD is frequently observed in association with other organ disease such as pancreatitis and sialadenitis [21,22,24], it should be emphasized that pleural effusions in IgG4-RD without other organ involvement are also increasingly recognized [25,26–28,29,30]. Pleural effusions in IgG4-RD are exudative with cellular constituents rich in lymphocytes and plasma cells. Histopathological examination of biopsied pleura reveals fibrinous pleuritis with lymphoplasmacytic inflammation including numerous IgG4-positive plasma cells and active fibrosis. Plasma cell infiltration with more than 10 IgG4-positive plasma cells/high power field and an IgG4/IgG-positive plasma cell ratio of more than 40% are suggestive of IgG4-RD for biopsied specimens [31].

Two independent studies have recently reported the association of IgG4 with pleural effusions of idiopathic cause [29,30]. Murata et al. [29] reported that 12 of 35 (34%) patients with pleural effusions undiagnosed during follow-up (median, 5 years; range, 1–10 years) were found to have marked IgG4-positive plasma cell infiltration in the pleura by IgG4 immunostaining along with elevated effusion IgG4 concentrations (Figs. 1 and 2). This study was the first to estimate the frequency of the IgG4-associated cause in idiopathic pleural effusions. Consistently, Kasashima et al. [30] reported that 8/22 (36%) of patients with fibroinflammatory pleural lesions of idiopathic cause met defined diagnostic criteria for IgG4-RD. In this study, 6/8 (75%) patients with IgG4-related pleural lesion had pleural effusions.

**KEY POINTS**

- IgG4-RD accounts for a proportion of patients with pleural effusions of idiopathic cause.
- Pleural effusions occur in IgG4-RD with or without associated extrathoracic manifestations.
- The possibility of IgG4-RD should be considered in patients with unexplained pleural effusions showing IgG4-positive plasma cell infiltration in pleural biopsies and/or pleural fluid cell blocks.
- IgG4-related pleural lesions are responsive to systemic steroid therapy.

![FIGURE 1](image)

(a) Chest radiographs of IgG4-related disease with bilateral pleural effusions in a 75-year-old man. Before (left) and 2 months after the steroid therapy at prednisolone 25 mg/day (right). (b) Chest computed tomography scan of the same patient before the steroid therapy. No specific finding is seen except pleural effusion.

1070-5287 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.co-pulmonarymedicine.com 385
effusions, which was the most common manifestation of IgG4-related pleural lesion. No extrapulmonary involvement in IgG4-RD was observed in the majority of patients with pleural effusion in these two studies. Kasashima et al. also reported a comparable histological feature of IgG4-positive plasma cell infiltration in the pleural biopsy specimens and the pleural fluid cell blocks, showing the utility of pleural fluid cell blocks for supporting the diagnosis of IgG4-RD. Thus, it is worth examining cases of undiagnosed pleural effusions by IgG4 immunostaining if other causes of effusion including malignancy are excluded with detailed exploration.

**DIAGNOSIS OF IgG4-RELATED PLEURAL LESION**

Establishing a diagnosis of IgG4-RD is based on international consensus histopathology criteria [31] in the context of clinical, biochemical, radiological and histological correlation. The critical histopathological features are a dense lymphoplasmacytic infiltrate, obliterative phlebitis and storiform fibrosis, and the presence of more than 10 IgG4-positive plasma cells per high-power field and an IgG4/IgG-positive plasma cell ratio of more than 40% are secondary in importance. On the other hand, epithelioid cell granuloma, a prominent neutrophilic infiltrate, abscess and necrosis are relatively inconsistent with the diagnosis of IgG4-RD. It should be noted that the pulmonary histopathology in IgG4-RD is different from that of more solid organs such as pancreas or kidney, and storiform fibrosis may not be a prominent feature in thoracic IgG4-RD [22,23,32]. In addition, either storiform fibrosis or obliterative phlebitis cannot always be observed in biopsy specimens [33]. Overall, IgG4-RD should not be diagnosed based on biopsy alone, and careful and deliberate clinicopathological correlation is needed when pleural effusion is the only manifestation of the disease.
IgG4-RD is a disease of middle-aged to elderly patients, with an average age of 50.3 ± 14.9 years at disease onset \((n = 125, \text{ mean } \pm \text{ SD, range } 12–82 \text{ years})\) and predominates in men (60.8%) [34]. Elevated serum IgG4 (≥135 mg/dl) was once presumed to be a hallmark of the disease but was not found to be observed in nearly 50% of biopsy-proven, clinically active IgG4-RD patients [34]. Consistent with this finding, pleural fluid IgG4 level may not be elevated in all patients with IgG4-related pleural lesion [29\textsuperscript{*}]. In contrast, approximately 5% of healthy individuals have elevated serum IgG4 levels. Therefore, relying on IgG4 levels alone may result in under-diagnosis or over-diagnosis, and the lack of elevated IgG4 level does not exclude this diagnosis. Inflammatory markers such as C-reactive protein and LDH levels are often within normal limits in IgG4-RD [30\textsuperscript{*},35] although LDH levels were elevated in some cases [25\textsuperscript{*},36]. In general, IgG4-RD tends to show relatively weak inflammation signs [37]. Adenosine deaminase (ADA) level in pleural fluid is associated with the activation of lymphocytes and is widely used in the auxiliary diagnosis of tuberculous pleuritis [38]. Although ADA is often normal in pleural effusions of IgG4-RD [28,30\textsuperscript{*}], elevated ADA levels (>40 IU/l) were also reported in pleural fluids of some IgG4-RD patients [26,39] and careful workup is needed to differentiate IgG4-related pleural lesion from tuberculous pleuritis by combination with Ziehl-Neelsen stain, PCR, cultures on solid and liquid media, IFN-\(\gamma\) release assay, pleural biopsy and so on.

Common radiologic features of thoracic involvement in IgG4-RD include pleural thickening, mediastinal lymphadenopathy, bronchial wall thickening and pericarditis [40,41], but these radiographic findings are not always detected in isolated pleural involvement in IgG4-RD. A fluorodeoxyglucose-PET (FDG-PET) is not recommended to detect pleural lesions because accumulation of FDG is not always noted in the pleura of patients with isolated IgG4-related pleural lesion [26,28]. When thoracic IgG4-RD is suspected, cervical and abdominal computed tomography should also be performed to examine the presence of extrathoracic lesions of IgG4-RD.

**DIFFERENTIAL DIAGNOSIS**

In differential diagnosis of IgG4-RD, several multi-organ diseases including sarcoidosis, connective tissue disease, lymphoma and multicentric Castleman’s disease (MCD) need to be ruled out because of the association with pleural effusion and IgG4.

Sarcoidosis can often exhibit hilar/mediastinal lymphadenopathy. Serum angiotensin converting enzyme level would be useful for differential diagnosis whereas soluble IL-2 receptor level in serum may not because it can rise in both IgG4-RD and sarcoidosis. Histologically, epithelioid granuloma is common in sarcoidosis while IgG4-RD is characterized by lymphoplasmacytic infiltration rich in IgG4-positive plasma cells.

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), two of the most common connective tissue diseases, are important in differential diagnosis. Although SLE is considered a disease of a young woman, lung involvement is more common in men. The presence of pleural disease is often accompanied by multisystem involvement [42] and clinical features of SLE including specific cutaneous manifestations can be helpful in distinguishing SLE from IgG4-RD. Serum antinuclear antibodies have been used as a serological test for diagnosis of SLE, and the pleural effusion antinuclear antibodies at a titer of at least 1:160 is a sensitive and specific diagnostic biomarker in SLE [43]. Patients with RA and pleural effusion are usually middle-aged men (>50 years), with high titers of rheumatoid factor, rheumatoid nodules and a higher prevalence of HLA-B8. Pleural effusion tends to occur in patients with long-standing arthritis, usually appearing years after the diagnosis of RA.

Lymphoma accounts for 6–15% of malignant pleural effusions and resembles IgG4-RD histologically. Pleural effusion cytology is important in the initial diagnosis of lymphoma [44]. Further studies including flow cytometry, morphology and immunohistochemistry are performed to determine monoclonality and karyorrhexis of lymphocytes for differential diagnosis. Although pleural involvement in lymphoma is commonly associated with widespread systemic disease, primary effusion lymphoma can occur as a distinct clinicopathological entity caused by human herpesvirus-8 and HIV infection [45,46]. In addition, there are series of cases describing lymphomas detected concurrently or asynchronously with IgG4-RD. The majority of these cases are reported to be MALT lymphomas occurring in the ocular adnexa, but lymphomas in IgG4-RD may be more varied in location and type [47]. Although it remains unknown whether IgG4-RD confers an increased risk of lymphoma, pathologists need to be aware of the potential for lymphoma to develop in patients with IgG4-RD.

MCD is a polyclonal lymphoproliferative condition characterized by lymphoplasmacytic infiltration with IgG4-positive plasma cells similarly to IgG4-RD but differs in responsiveness to corticosteroids. MCD presents multiple lymphadenopathy and involvement of lung parenchyma [35], and hence the differentiation of MCD from IgG4-RD can be sometimes difficult. MCD patients are
significantly younger than those with IgG4-RD, and serum C-reactive protein levels are elevated in contrast to those in IgG4-RD patients [48]. Elevated serum IL-6 level is also useful to distinguish MCD from IgG4-RD [48].

**PATHOGENESIS OF IgG4-RELATED DISEASE**

The pathophysiology of IgG4-RD remains largely unknown, but remarkable insights to the disease pathogenesis have been recently reported. IgG4 antibodies are generally known as anti-inflammatory, due to the inability to bind to complement component C1q, low affinity to Fcy receptors and the ability to exchange Fab-arms. Consistent with these anti-inflammatory properties of IgG4 antibodies, injection of IgG1 antibodies of patients with IgG4-RD into neonatal BALB/c mice resulted in pancreatic and salivary gland injuries, but the pathogenic effects of IgG1 antibodies were attenuated when IgG4 antibodies were simultaneously injected [49**]. Notably, IgG4 from IgG4-RD patients had also pathogenic activity although the extent of the injuries was significantly lower in mice injected with IgG4 than with IgG1. The same groups identified laminin 511-E8, one of the extracellular matrix proteins, as the target antigen [50]. Other target antigens identified to date include annexin A11, a 56-kDa cytotoxic protein, from human H69 cholangiocyte lysates [51] and galectin-3, a β-galactoside-binding lectin [52]. Furthermore, T follicular helper (Tfh) cells that are involved in the differentiation of naïve B cells into IgG4-producing plasmablasts are found to be expanded in IgG4-RD [53]. Tfh2 cells, a subset of Tfh cells, induce Ig class switching in B cells via secretion of IL-4. The Tfh2 cell count in blood is shown to be correlated with disease activity and may serve as a potential biomarker [53,54**]. In addition, a novel population of CD4⁺ effector T cells with cytotoxic function (CD4⁺ cytotoxic T lymphocytes) has been found to expand in the circulation and affected tissues in IgG4-RD patients [55]. This novel subset of CD4⁺ T cells arises from chronic antigen stimulation, due to downregulation of the transcription factor ThPOK, and expresses SLAMF7, granzyme A, proinflammatory IL-1β and profibrotic TGF-β1, presumably associated with the fibroinflammatory condition of the disease.

**TREATMENT**

Treatment of pleural effusion depends on the severity of symptoms. Isolated pleural involvement of IgG4-RD without multisystem disorder usually follows a benign course, and a watchful waiting with radiographic follow-up is appropriate in patients with small and asymptomatic effusions. On the other hand, patients with pleural effusion accompanying involvement of vital organs, including aortitis, periarteritis, pancreatic enlargement and tubulointerstitial nephritis should be treated urgently because delay in treatment may result in irreversible organ dysfunction [56]. For active IgG4-RD, glucocorticoids are recognized as the first-line treatment [56] and are shown to improve pleural fluids and respiratory symptoms in patients with IgG4-related pleural lesion [25*,26–28,29*,30**,39,57]. Japanese consensus criteria recommends prednisolone of 0.5–0.6 mg/kg/day as the initial dose, and this dose can be gradually weaned over subsequent months, depending on the improvement of clinical, laboratory and radiographic features [58]. There is no significant difference in remission induction between high (0.8–1.0 mg/kg/day) and medium doses of glucocorticoids (0.5–0.6 mg/kg/day) [59]. However, the high relapse rate both during and after glucocorticoid tapers in IgG4-RD is a hindrance to this therapy, and a maintenance dose of 5–10 mg/day of prednisolone is recommended for more than 1 year [58]. As an alternative to glucocorticoids, B-cell depletion with rituximab (1 g at days 0 and 15) has been assessed in a prospective open-label trial with 30 IgG4-RD patients, showing disease responses in 97% of patients [60]. A French retrospective study with 33 IgG4-RD patients showed the effectiveness of rituximab for both remission induction and retreatment for relapse and increased relapse-free survival [61]. The rituximab treatment resulted in a concomitant decrease in the numbers of circulating plasmablasts and CD4⁺ SLAMF7⁺ cytotoxic T lymphocytes but not CD4⁺ GATA3⁺ Tfh2 cells or CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells in peripheral blood of IgG4-RD patients [55]. These findings contribute to a better understanding of this novel immune-mediated disorder as well as other autoimmune diseases.

**CONCLUSION**

Pleural effusion of IgG4-RD is an under-recognized pleural condition. Pleural involvement in IgG4-RD can occur in isolation, or association with extrapulmonary manifestations. In patients with pleural effusion of unexplained cause, IgG4-RD should be considered when lymphoplasmacytic infiltration with IgG4-positive plasma cells is observed in pleural biopsy specimens because this condition responds well to systemic steroid therapy. IgG4 immunostaining of pleural fluid cell blocks can be supportive for the diagnosis of IgG4-related pleural lesion. Importantly, the possibility of IgG4-RD
should be evaluated through multidisciplinary processes in the context of clinical, radiological and histological correlation. It is presumed that pleural effusions in IgG4-RD occur at higher than expected prevalence. Further studies with large numbers of patients are needed to determine the true prevalence of pleural effusion related to IgG4.

Acknowledgements

We would like to thank Drs Tomoyuki Murakami and Nobuyuki Tanaka for helpful discussion and Mr Masazumi Tanaka, Ms Masami Murakami, Ms Mai Nitta and Ms Yuka Mimura-Kimura for technical assistance.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as: ■ of special interest ■ of outstanding interest

1. Light RW, Lee YCG. Textbook of pleural diseases. Boca Raton: CRC Press; 2016.
2. Feller-Kopman D, Light R. Pleural disease. Philadelphia: Lippincott Williams & Wilkins; 2013.
3. Ryu JH, Sekiguchi H, Yi ES. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J 2012; 39:180–186.
4. Porcelli S. Advances in the diagnosis of tuberculosis pleuritis. Ann Trans Med 2016; 4:282.
5. Umehara H, Nakajima A, Nakamura T, et al. IgG4-related disease and its clinicoradiological and pathological features. Respirology 2013; 18:480–487.
6. Matsu S, Hebisawa A, Sakai F, et al. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respir Med 2018; 132:593–597.
49. Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut 2016; 65:1322–1332. The study elegantly demonstrates the pathogenic activities of IgG1 and IgG4 antibodies from IgG4-RD patients by passive transfer to mice and the inhibitory effect of IgG4 antibodies on the IgG1-induced pancreatitis.

50. Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med 2018; 10: eaaw9997.

51. Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 2018; 67:728–735.

52. Perugini CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol 2019; 143:736–745.e6.

53. Akiyama M, Yasuoka H, Yamaoka K, et al. Enhanced IgG4 production by follicular helper T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther 2016; 18:167.

54. Akiyama M, Suzuki K, Yasuoka H, et al. Follicular helper T cells in the pathogenesis of IgG4-related disease. Rheumatology (Oxford) 2018; 57:236–245. This provides an overview of the roles of various T cell subsets in the pathogenesis of IgG4-RD.

55. Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 2016; 138:825–838.

56. Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guideline statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015; 67:1688–1699.

57. Sekiguchi H, Hori R, Utz JP, Ryu JH. IgG4-related systemic disease presenting with lung entrapment and constrictive pericarditis. Chest 2012; 142:781–783.

58. Masaki Y, Shimizu H, Sato Nakamura T, et al. IgG4-related disease: diagnostic methods and therapeutic strategies in Japan. J Clin Exp Hematop 2014; 54:95–101.

59. Wu G, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis 2017; 20:639–646.

60. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74:1171–1177.

61. Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 2017; 12:e0183844.